| Spirit Lake Health Center | |
|
3883 74th Ave Ne Ft Totten ND 58301 | |
| (701) 766-1612 | |
| Not Available |
| Full Name | Spirit Lake Health Center |
|---|---|
| Speciality | Clinic/center - Public Health, Federal |
| Location | 3883 74th Ave Ne, Ft Totten, North Dakota |
| Authorized Official Name and Position | Darren Martell (BUSINESS OFFICE MANAGER) |
| Authorized Official Contact | 7017661600 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Spirit Lake Health Center Po Box 309 3883 74th Ave Ne Fort Totten ND 58335-0309 Ph: () - | Spirit Lake Health Center 3883 74th Ave Ne Ft Totten ND 58301 Ph: (701) 766-1612 |
| NPI Number | 1548323314 |
|---|---|
| Provider Enumeration Date | 12/19/2006 |
| Last Update Date | 08/22/2020 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548323314 | NPI | - | NPPES |
| 01056 | Medicaid | ND | |
| 3503693 | Other | ND | NCPDP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP0904X | Clinic/center - Public Health, Federal | AU46983207 (* (Not Available)) | Primary |
News Archive
The Paulig Eye Surgery Centre announces today that it has acquired advanced technology for performing Keraflex KXL, a new, non-invasive, non-surgical treatment for keratoconus. Surgeons at the Paulig Eye Surgery Centre will immediately begin treating patients using Avedro, Inc's Keraflex and KXL Systems.
The Wall Street Journal: German hospitals are worried that the end of compulsory military service could hurt their workforce as most young German men end up fulfilling their duties there and in other public-service venues. "Increasingly … conscription's main impact has little to do with military training at all.
Ario Pharma Ltd, the Cambridge biopharmaceutical company developing innovative new approaches to treat respiratory disease, announced today that it has commenced a Phase IIa study of its TRPV1 antagonist, XEN-0501, for the treatment and prevention of cough in patients with chronic obstructive pulmonary disease (COPD). Persistent cough in COPD and other respiratory conditions present as a huge unmet medical need, with novel therapies urgently needed to improve the quality of life of patients.
Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.
Rheonix, Inc., developer of the Rheonix CARD system that provides a powerful microfluidic platform for the evolving molecular diagnostics industry, announced that on June 14, 2011 the U.S. Patent and Trademark Office will issue Patent Number 7,959,875, "Microfluidic Chips and Assay Systems," and on April 13, 2011 it allowed Patent Application Number 11/594,444, "Microfluidic Systems," to the Company.
› Verified 2 days ago